Gapping up
In reaction to earnings/guidance:
- IP +5.5%, SYM +5.4%, SPOT +5.2%, SANM +4.9%, GM +4.6%, ALGM +3.5%, VSCO +3.3%, CSWC +3.1% (also increases dividend), AOS +2.5%, WHR +2.1%, HP +2%, PHM +1.5%, UPS +1.4%, GGG +1.2%, PSX +0.9%
Other news:
- CRK +6.3% (replacing ADC in the S&P SmallCap 600)
- FENC +4.6% (announces PEDMARK (sodium thiosulfate injection) receives Orphan Drug exclusivity from FDA)
- IONS +1.8% (FDA grants olezarsen Fast Track designation for the treatment of familial chylomicronemia syndrome)
- GABC +1.6% (increases quarterly dividend)
- QURE +0.8% (entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 amyotrophic lateral sclerosis a rare genetic form of ALS)
- ALGT +0.7% (announces management changes; Robert Neal named CFO)
Analyst comments:
- INTR +5.3% (upgraded to Buy from Neutral at Goldman)
- FGEN +2.4% (upgraded to Outperform from Mkt Perform at William Blair)
- NFE +0.7% (upgraded to Buy from Neutral at BTIG Research)